Drugs / EB-701/CA9-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07551349 | Feb 2026 → Apr 2027 expected | clear cell renal carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-701/CA9-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551349 ↗ |
| Action | Deplete | “innate NK killing as a complementary antitumor mechanism” NCT07551349 ↗ |
| Modality | Cell therapy | “allogeneic CAR-NK strategy” NCT07551349 ↗ |
| Target | CA9 | “dual CAR recognizing CD70 and CAIX/CA9” NCT07551349 ↗ |
| Target | CD70 | “dual CAR recognizing CD70 and CAIX/CA9” NCT07551349 ↗ |